Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

24432 ARTÍCULOS , VIENDO DEL 19876 AL 19890

Anti-TNF-α reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains

Shi JQ, Shen W, Chen J, Wang BR, Zhong LL, Zhu YW, Zhu HQ, Zhang QQ, Zhang YD, Xu J.

Brain Res. 2011 Jan 12;1368:239-47. doi: 10.1016/j.brainres.2010.10.053. Epub 2010 Oct 21.

Is dementia preventable? Focus on Alzheimer's disease

Barak Y, Aizenberg D.

Expert Rev Neurother. 2010 Nov;10(11):1689-98. doi: 10.1586/ern.10.159.

Video-based coping skills to reduce health risk and improve psychological and physical well-being in Alzheimer's disease family caregivers

Williams VP, Bishop-Fitzpatrick L, Lane JD, Gwyther LP, Ballard EL, Vendittelli AP, Hutchins TC, Williams RB.

Psychosom Med. 2010 Nov;72(9):897-904. doi: 10.1097/PSY.0b013e3181fc2d09. Epub 2010 Oct 26.

[Memantine in the pharmacologic treatment of moderately severe to severe Alzheimer's disease in Spain (MEMORY study)]

Agüera-Ortiz LF; Grupo de Investigadores del Estudio MEMORY.

Rev Neurol. 2010 Nov 1;51(9):525-34.

APOE varepsilon2 and presymptomatic stage Alzheimer disease: how much is not enough?

Caselli RJ, Dueck AC.

Neurology. 2010 Nov 30;75(22):1952-3. doi: 10.1212/WNL.0b013e3181ff94f7. Epub 2010 Oct 27.

Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease

Kayed R.

Hum Vaccin. 2010 Nov;6(11):931-5. doi: 10.4161/hv.6.11.12689. Epub 2010 Nov 1.

Simplified β-amyloid peptides for safer Alzheimer's vaccines development

Verdoliva A, Rivieccio V, Rossi M.

Hum Vaccin. 2010 Nov;6(11):936-47. doi: 10.4161/hv.6.11.13034. Epub 2010 Nov 1.

Brain fuel metabolism, aging, and Alzheimer's disease

Cunnane S, Nugent S, Roy M, Courchesne-Loyer A, Croteau E, Tremblay S, Castellano A, Pifferi F, Bocti C, Paquet N, Begdouri H, Bentourkia M, Turcotte E, Allard M, Barberger-Gateau P, Fulop T, Rapoport SI.

Nutrition. 2011 Jan;27(1):3-20. doi: 10.1016/j.nut.2010.07.021. Epub 2010 Oct 29.

Phosphorylation of APP-CTF-AICD domains and interaction with adaptor proteins: signal transduction and/or transcriptional role--relevance for Alzheimer pathology

Schettini G, Govoni S, Racchi M, Rodriguez G.

J Neurochem. 2010 Dec;115(6):1299-308. doi: 10.1111/j.1471-4159.2010.07044.x. Epub 2010 Nov 4.

α-secretase in Alzheimer's disease: molecular identity, regulation and therapeutic potential

Lichtenthaler SF.

J Neurochem. 2011 Jan;116(1):10-21. doi: 10.1111/j.1471-4159.2010.07081.x. Epub 2010 Dec 2.

Switching cholinesterase inhibitors in older adults with dementia

Massoud F, Desmarais JE, Gauthier S.

Int Psychogeriatr. 2011 Apr;23(3):372-8. doi: 10.1017/S1041610210001985. Epub 2010 Nov 3.

Clinical and economic characteristics associated with direct costs of Alzheimer's, frontotemporal and vascular dementia in Argentina

Rojas G, Bartoloni L, Dillon C, Serrano CM, Iturry M, Allegri RF.

Int Psychogeriatr. 2011 May;23(4):554-61. doi: 10.1017/S1041610210002012. Epub 2010 Nov 3.

In-vivo histamine H3 receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer's disease

Bitner RS, Markosyan S, Nikkel AL, Brioni JD.

Neuropharmacology. 2011 Feb-Mar;60(2-3):460-6. doi: 10.1016/j.neuropharm.2010.10.026. Epub 2010 Oct 31.

Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial

Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR Jr, Weiner M, Shinto L, Aisen PS.

JAMA. 2010 Nov 3;304(17):1903-11. doi: 10.1001/jama.2010.1510.

Inflammation and Alzheimer's disease

Lee YJ, Han SB, Nam SY, Oh KW, Hong JT.

Arch Pharm Res. 2010 Oct;33(10):1539-56. doi: 10.1007/s12272-010-1006-7. Epub 2010 Oct 30.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias